Ly6G is a GPI-anchored protein of unknown function that is commonly targeted to induce experimental neutrophil depletion in mice. We found that doses of anti-Ly6G
Introduction
Neutrophils are one of the first cell types to reach sites of infection or acute inflammation. Recruitment involves an orchestrated sequence of events in which circulating neutrophils respond to chemotactic signals to become firmly adherent to activated endothelium, followed by transendothelial migration via either a paracellular or transcellular route. 1, 2 Once at a site of inflammation, neutrophils contribute to ongoing leukocyte recruitment and tissue injury by releasing lipid mediators, proteases, reactive oxygen species, and other factors. [3] [4] [5] While critical to immune defense, neutrophils can play a pathogenic role in chronic inflammatory diseases. Therefore, their recruitment is subject to numerous levels of control, not all of which are completely understood. 1 Delineating these regulatory pathways will provide insights into the mechanisms of tissue injury in inflammatory disorders and novel targets for drug development.
Much of the experimental evidence implicating neutrophils in disease has been obtained through murine studies in which this lineage was selectively depleted using antibodies that bind the neutrophil surface antigen Ly6G, such as RB6-8C5 (more typically termed anti-Gr-1). 6, 7 However, the function of Ly6G remains unknown. Ly6G is a small protein of approximately 25 kD, tethered to the cell surface via a glycosylphosphatidylinositol (GPI) linker. 7 In bone marrow, peripheral blood, and wound exudates, expression of Ly6G is limited to cells with granulocyte morphology. 7, 8 Structurally, Ly6G belongs to the Ly6/uPAR (urokinase plasminogen activator receptor)
family of proteins featuring a "three finger fold" motif stabilized by 4-5 disulfide bonds. 9 For personal use only. on October 31, 2017. by guest www.bloodjournal.org From These protein folds are believed to create a docking site for other molecules. However, no ligand for Ly6G has been identified. Furthermore, while other members of the Ly6/uPAR family have been implicated in signaling, presumably by association with transmembrane proteins, no signaling function for Ly6G has been defined. [9] [10] [11] Ly6G is expressed only in mice, but a structurally related Ly6/uPAR family member, CD177
(also called HNA-2a, NB1 or PRV-1), is expressed in human neutrophils and has been implicated in some cases of human immune neutropenia. 12 CD177 exhibits a direct association with β2 integrins. [12] [13] [14] CD177 is a counter-receptor for PECAM-1, and antibodies against CD177 impede neutrophil migration across an endothelial barrier. 15 The extent of functional homology between murine and human proteins of the Ly6/uPAR family remains undefined.
Recently, data have begun to emerge that ligation of Ly6G via specific antibodies may have functional consequences beyond physical depletion. TNFα-primed mice given anti-Gr-1 (which binds both Ly6G and the structurally related protein Ly6C) 7, 8 or the Ly6G-specific antibody 1A8 (hereafter anti-Ly6G) develop disseminated intravascular coagulation and death. 16, 17 In vitro, cross-linking using anti-Gr-1 F(ab') 2 fragments and a secondary antibody induces upregulation of neutrophil CD11b as well as a modest rise in F-actin, though whether this phenomenon reflects binding of Ly6G, Ly6C or both is unknown. 17 Anti-Gr-1 administration has also been associated with the appearance of apoptotic-appearing neutrophils in inflammatory infiltrates, giving rise to the hypothesis that anti-Gr-1 induces apoptosis in circulating or inflammatory neutrophils,
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From but not in their marrow precursors, potentially due to differential expression of the antiapoptotic Bcl-2 family protein Mcl- 1. 18 In human arthritis, neutrophils are invariably present in the inflamed joint. 19, 20 The pathogenic contribution of these cells has been confirmed experimentally in conventional depletion experiments using anti-Gr-1, as well as by studies in genetically neutropenic mice. [20] [21] [22] [23] While investigating the effect of partial neutropenia in murine K/BxN arthritis, we made the unexpected observation that low doses of anti-Gr-1 with minimal sustained effect on circulating neutrophil counts nevertheless led to dramatic attenuation of disease. Subsequent studies using anti-Ly6G confirmed this observation, and identified impairment of neutrophil migration rather than accelerated apoptosis as the most plausible explanation. We found that Ly6G associated closely with β2 integrins, and that anti-Ly6G attenuated both β2 integrin expression and function, a role implicated in the efficacy of antibody treatment. Together, these results imply a previously unappreciated function for this highly-expressed neutrophil protein, suggesting a novel mechanism regulating neutrophil recruitment to inflamed sites.
Further, they demonstrate previously unrecognized similarities with CD177 that render study of Ly6G potentially informative as to this non-homologous human counterpart.
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Material and Methods

Reagents
Endotoxin-free anti-Gr-1, anti-Ly6G and isotype control (rat IgG2a, clone 2A3) were obtained from BioXCell (West Lebanon, NH). Endotoxin-free anti-Ly6B.2 (clone 7/4) was from AbD Serotec (Oxford, UK). Anti-CD18, anti-CD11b-FITC, H 2 DCFDA, phalloidin-Alexa 488, and Live/Dead® staining reagent were from Invitrogen (Carlsbad, CA), CD45-PE-Cy7 and Annexin V staining reagents from BD Pharmingen (San Diego, CA). Anti-CD11a-Alexa 488, anti-CD11a-biotin, anti-Ly6G-Alexa 647, anti-CD11a-PE, anti-CD11b-Alexa 488, anti-Ly6G-biotin, anti-Ly6G-Alexa 647, anti-CD62L-APC and anti-Gr-1-Alexa 647 from Biolegend (San Diego, CA), streptavidin-Cy3 and streptavidinAlexa 594 from Jackson ImmunoResearch (West Grove, PA). NIMP-R14 from AbCam (Cambridge, MA). PMA, murine TNFα, and staurosporine were purchased from SigmaAldrich (St. Louis, MO), and LTB 4 from Cayman Chemical (Ann Arbor, MI). 
Mice
Experimental arthritis
Arthritogenic serum was obtained from 9-11 week old K/BxN donors by cardiac puncture as described. 24 Arthritis was initiated with i.p. injections of 150 μl K/BxN serum on experimental days 0 and 2. To measure severity of disease, each paw was graded on a scale of 0-3, for a total score of 0-12 per mouse. Normal paws were scored 0; 1 additional point was given for swelling affecting the dorsal surface, ventral surface, ankle/wrist, and toes, capping at a maximum of 3. 25 "Flare" (transient paw swelling) was assessed on the same scale 30 min after serum administration. 26 Histological assessment of articular neutrophils was accomplished using NIMP-R14 antibody staining. 27 Interpretability of staining in the context of anti-Ly6G administration was confirmed by intact staining of marrow cells with neutrophil morphology in the sections analyzed.
Experimental peritonitis
Peritonitis was initiated by instillation of 1 ml sterile aged 3% thioglycollate (TG) broth i.p.
4 h prior to harvest. The peritoneum was lavaged with 2 ml PBS and cells enumerated by flow cytometry using synthetic 15 μm microspheres (Polysciences, Warrington PA) to normalize counting between specimens (Polysciences, Warrington PA). For apoptosis studies, peritoneal cells were harvested with warm RPMI/0.1% FBS.
Neutrophil quantitation
For neutrophil enumeration, blood was harvested by cardiac puncture from lethally anesthetized mice and transferred immediately into EDTA-containing VacuTainer tubes 
Studies of neutrophil migration and activation
All media and centrifuges were maintained at room temperature. For migration studies, bone marrow was harvested by marrow flush with RPMI, passed through a 100 μm filter, centrifuged for 3 min at 300 x g (~1300 rpm) and resuspended in RPMI containing 0.1%
heat-inactivated FBS. Cell suspensions were exposed to anti-Ly6G or isotype for 10 min at RT. Thereafter 500 μL of cells were placed in the upper compartment of a transwell chamber featuring 3 μm pores in an uncoated polycarbonate membrane (Corning, Corning NY), while 1.5 ml 0.1% FBS RPMI media containing LTB 4 2A3 (10 μg/ml) or anti-Ly6G (10 μg/ml) for 10 min, marrow cells were washed with icecold FACS buffer and stained for neutrophil surface markers. Cells were then fixed with 4% paraformaldehyde in PBS for 15 min, permeabilized with 0.5% Triton X-100 for 10 min, and stained with labeled phalloidin in FACS buffer containing 0.05% saponin.
Isolation of mouse neutrophils from bone marrow
Mouse neutrophils were isolated by flushing femurs and tibias with RPMI containing 0.1% FBS. After depletion of erythrocytes using ACK lysis buffer, cells were resuspended in Ca/Mg-free Hank's balanced salt solution (HBSS) buffer, loaded on a discontinuous Percoll density gradient (63%/81%), and centrifuged at 1000 g for 30 min.
This procedure routinely yielded > 90% neutrophils as determined by flow cytometry. 2 -FITC was applied to neutrophils at 4°C for 30 min to detect active β2 integins.
ICAM-1-Fc binding assay
Flow chamber assay
Murine endothelial bEND5 cells were grown to confluence in 60 mm culture dishes and activated for at least 3 h with murine TNFα 5 mM as described. 31 Neutrophils purified from B6 bone marrow by density centrifugation were treated with isotype antibody or anti-Ly6G (10 μg/ml at RT for 10 min), resuspended at 2 x 10 6 cells/ml in HBSS, 10 mM HEPES with either 2 mM Ca 2+ /2 mM Mg 2+ or 5 mM EDTA, and introduced into the flow assay chamber. Tethering of neutrophils was observed at low physiologic wall shear stress (0.5 dyne/cm 2 for 1 min). Firm adhesion was observed at high physiologic shear stress (3 min pause, 0.5 dyne/cm 2 for 1 min followed by stepwise increases to 10 dyne/cm 2 ) as described. 
In situ cross-linking and co-immunoprecipitation
Cross-linking of protein complex was performed in cell using 3 mM DTBP in conjugation buffer (20 mM sodium phosphate, 150 mM NaCl, pH 8.0) for 45 min at RT, followed by 
Statistical analysis
Error bars depict SD, aside from arthritis clinical score plots and FLIM analysis where they reflect SEM. P values were calculated using Student's t-test unless otherwise indicated in figure legends. P values < .05 were considered significant.
Results
Anti-Gr-1 blocks K/BxN serum transfer arthritis at non-depleting doses
In K/BxN serum transfer arthritis, parenteral administration of serum containing IgG autoantibodies directed against the glycolytic enzyme glucose 6 phosphate isomerase results in rapid onset of destructive joint inflammation (synovitis) in most recipient strains of mice. The essential role of neutrophils in this process was previously demonstrated by studies in which repeated administration of anti-Gr-1 (250 μg i.p.) was found to both prevent and treat disease. 20 To study the relative contribution of various innate immune lineages to synovitis, we sought to generate incomplete neutropenia using lower doses of antibody. Anti-Gr-1 was administered i.p. to B6 mice on day -1 and was not entirely dependent on depletion of circulating neutrophils but might also be mediated by altered neutrophil function.
Ly6G-selective antibody attenuates arthritis and inhibits neutrophil recruitment in vivo
Although widely used in neutrophil studies, anti-Gr-1 also recognizes Ly6C, an antigen expressed on monocytes and other lineages. Correspondingly, high-dose anti-Gr-1 depletes monocytes in addition to neutrophils. 8 For further investigation, we therefore employed the Ly6G-selective antibody 1A8. 
Search for a functional impact of Ly6G ligation
Neutrophil involvement in murine autoantibody-mediated arthritis proceeds in 4 stages. (Figure 2A , B and C). We therefore focused our investigation on neutrophil death and migration.
Antibody ligation of Ly6G at low dose does not induce neutrophil apoptosis
Recently, Ribechini et al. reported that instillation of anti-Gr-1 (250 μg i.p.) following recruitment of neutrophils to peritoneum via i.p. TG resulted in the depletion of neutrophils and the appearance of pyknotic nuclei, suggesting induction of apoptosis.
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Indeed, accelerated neutrophil apoptosis is a recognized basis for resistance to 38, 41 We therefore considered whether low-dose anti-Ly6G might induce apoptosis of neutrophils activated in the process of recruitment. To explore this possibility, we exposed bone marrow neutrophils and neutrophils obtained from TGstimulated peritoneum to anti-Ly6G or control. Apoptosis was assessed over the course of 48 h by staining for Annexin V. While activated neutrophils entered apoptosis more rapidly, as expected, no specific pro-apoptotic effect of anti-Ly6G was observed ( Figure   3A ). To confirm this observation in vivo, we pre-treated animals with anti-Ly6G and induced TG peritonitis to look for excess apoptosis in recruited neutrophils, as is readily apparent when TG peritonitis is induced in Foxo3a -/-mice susceptible to accelerated apoptosis. 38 Again, no difference in apoptosis could be observed ( Figure 3B ). These results are consistent with the lack of pyknotic neutrophils in anti-Ly6G-treated day 4
ankle tissues ( Figure 2C ). We therefore suspect that the pro-apoptotic mechanism defined by Ribechini et al. using high-dose anti-Gr-1 antibody is not decisive for suppression of arthritis by low-dose anti-Ly6G.
Anti-Ly6G inhibits LTB 4 -induced neutrophil migration
We next evaluated whether anti-Ly6G might impair neutrophil migration. Unfractionated, washed bone marrow cells were pre-incubated with anti-Ly6G or isotype control and placed into the upper chamber of a transwell apparatus. Media containing LTB 4 , a chemoattractant required for initial migration of neutrophils to the joint, 39 was introduced into the lower chamber, and migrating neutrophils were enumerated by flow cytometry of cells harvested from the lower chamber after 3 h. Strikingly, anti-Ly6G specifically abrogated neutrophil migration in this system ( Figure 4A) . By contrast, the isotype- (Figure 4B) , excluding the possibility that the effect of anti-Ly6G arose simply due to neutrophil binding. Impaired migration was also found for C5a, f-Met-Leu-Phe and GM-CSF (Supplementary Figure   2) . To ensure that inhibition was not related to engagement of the inhibitory Fc receptor
FcγRII by tethered antibody, we replicated the experiment in FcγRII -/-cells and found an identical result ( Figure 4C ). The anti-Ly6G effect was also preserved in density-purified neutrophils that were free of associated or attached platelets as assessed by CD41
staining (Supplementary Figure 3) . Interestingly, while Fab fragments from anti-Ly6G still bound well to neutrophils, they failed to inhibit migration, implicating oligomerization of Ly6G in the mechanism of inhibited migration ( Figure 4D and Supplementary 
or hypersensitization: pretreatment with anti-Ly6G uniformly suppressed migration, rather than shifting the bell-shaped dose-response curve ( Figure 5B) . 43 These experiments indicate that the inhibitory effect of anti-Ly6G on LTB 4 -induced neutrophil migration lies downstream of the initial chemotactic signal.
Anti-Ly6G does not activate neutrophils
Since neutrophil migration requires physical deformation, we explored whether antiLy6G might "pre-activate" neutrophils, resulting in enhanced rigidity and therefore failure to cross the transwell membrane. Indeed, crosslinking of anti-Gr-1 F(ab')2 fragments induces F-actin and CD11b expression, while neutrophil activation might explain the lethal outcome of anti-Ly6G administration into TNFα-treated mice. 16, 17 We therefore employed a range of assays to assess neutrophil activation and endothelial adhesion.
We found no effect of anti-Ly6G on expression of the activation markers CD11b and CD62L, actin polymerization, generation of reactive oxygen species, or adherence to TNFα-activated murine endothelium under low physiologic wall shear stress (Figure 6 A-D). Thus, we could not identify direct activation of neutrophils by Ly6G ligation as used in our system.
Ly6G associates with β2 integrins
Recent studies on the human neutrophil Ly6/uPAR family member CD177 have identified an association with the β2 integrins CD11a/CD18 (LFA-1) and CD11b/CD18
(Mac-1). 14 Considering the possibility that CD177 and Ly6G could be functionally homologous, we examined the distribution of Ly6G and β2 integrins by high-resolution
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Further, following in-situ crosslinking, Ly6G and CD18 could reciprocally coimmunoprecipitate ( Figure 7B ). To confirm this interaction, we employed FLIM. As shown in Table 1 and the representative image in Figure 7C , the decrease in τ 1 indicates an interaction between Ly6G and CD11a and also between Ly6G and CD11b. This decrease was not seen when we probed the interaction between CD11b and CD45 ( Table 1) . Interestingly, the percentage of CD11a molecules interacting with Ly6G (a1%) was higher than that seen for CD11b. Taken together, these data strongly support a direct association of Ly6G with β2 integrins.
Blockade of migration by Ly6G ligation in activated neutrophils is mediated through β2 integrins
Recognizing that β2 integrins -in particular LFA-1 -are absolutely required for in K/BxN serum transfer arthritis, 44 we evaluated whether anti-Ly6G could affect integrin expression and function in activated neutrophils despite the absence of effect in nonactivated cells. We therefore examined neutrophils preincubated with anti-Ly6G or isotype and then exposed to LTB 4 integrins, anti-Ly6G no longer altered migration of CD18 -/-neutrophils. Together, these findings identify a previously undefined role for Ly6G as a functional modulator of neutrophil migration and implicate β2 integrins in this activity.
Our observations shed new light on Ly6G, a molecule whose targeting has been a mainstay of experimental murine immunology. We show that the effects of anti-Gr-1 and anti-Ly6G on neutrophil function surpass their impact on circulating neutrophil counts.
Our finding that anti-Ly6G abrogates integrin-mediated adherence comports well with
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From the finding that injection of anti-Gr-1 induces detachment of neutrophils from endothelium in vivo. 16 While we did not observe alteration in apoptosis, as reported by Ribechini et al., this difference may reflect the timing of treatment, the choice of agent (anti-Gr-1 vs. anti-Ly6G) or the dose employed (250 μg vs. 5-10 μg).
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Interestingly, in mice pre-treated with TNFα, administration of either anti-Gr-1 or anti-Ly6G promotes development of leukocyte/platelet aggregates, leading to disseminated intravascular coagulation. 16, 17 Anti-Gr-1-induced adherence between platelets and leukocytes was also found in mice with proteoglycan-induced arthritis, an effect replicated with anti-CD44 and also recombinant P-selectin-Fc fusion protein.
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Neutropenia induced by these agents could be attenuated by heparin or platelet depletion, suggesting that aggregate formation is an important mechanism of antibodymediated neutrophil depletion. 47 Further, a recent study in transfusion related acute lung injury (TRALI) found that abrogation of disease via anti-Gr-1 was mediated not through neutrophil depletion but rather by complement consumption; antibodies against erythrocytes were just as effective. 48 These results highlight the need to remain alert for experimental artifacts when employing cell-targeting antibodies. However, several lines of evidence suggest that our findings reflect the biology of Ly6G. In vivo, circulating neutrophil counts and morphology remained largely unchanged over the course of arthritis, and a neutrophil-binding antibody of matched isotype, anti-Ly6B.2, failed to attenuate arthritis. In vitro, platelets and complement were not required for either migration or endothelial adherence phenotypes. Thus, our results most likely reflect specific functions of Ly6G, though further investigation will be required to establish this mechanism in molecular detail.
Careful study of intravenous anti-Ly6G and anti-Gr-1 has identified transient reduction in circulating neutrophils, even at doses similar to those employed here. 17, 49 Studies using radiolabeled anti-Gr-1 suggest that tagged cells are cleared in the liver and spleen, and that neutrophils reconstituting the circulating pool are derived from the bone marrow. 49 If this is the case with low-dose anti-Ly6G, then some of its anti-arthritic effect might derive from reduced arthritogenic potency of freshly-released bone marrow neutrophils. However, we doubt that replacement represents a major mode of action of low-dose anti-Ly6G. First, the neutropenia we observe after antibody administration i.p.
is less profound than reported with intravenous dosing. Second, murine bone marrow and circulating neutrophils exhibit comparable functionality. 50 Indeed, adoptively transferred bone marrow neutrophils are quite capable of mediating K/BxN arthritis. While GPI-linked proteins cannot by themselves initiate intracellular events, they may Interest in these questions is heightened by similarities between Ly6G and the human neutrophil protein CD177. Our data indicate that Ly6G, like CD177, exhibits both spatial and functional interactions with β2 integrins. Further, antibody ligation of both molecules inhibits neutrophil migration, as demonstrated recently for CD177 using a transendothelial system 15 . These observations suggest that Ly6G may possess important functional homology with CD177, potentially providing an opportunity for in vivo experimental manipulation that is currently unavailable for the human protein.
Together, these results demonstrate a previously unrecognized activity for Ly6G ligation as a modulator of neutrophil migration, via a mechanism dependent on β 2 integrins. This observation is of interest not only because Ly6G is frequently targeted experimentally, but because our results imply the existence of a distinct new pathway regulating neutrophil migration in vivo, offering a potential therapeutic opportunity to control the participation of neutrophils in inflammatory disease.
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